Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
boston blog main
10
×
boston top stories
life sciences
10
×
national blog main
national top stories
10
×
clinical trials
fda
san francisco blog main
san francisco top stories
eli lilly
indiana blog main
indiana top stories
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
amgen
boston
cancer
deals
europe blog main
europe top stories
genentech
novartis
abbvie
allergan
What
drug
10
×
fda
10
×
approval
medicines
won
cancer
new
approved
blueprint
class
companies
designed
developed
marketing
medicine
migraine
oral
ret
therapeutics
therapy
treatment
weight
acquire
address
agency
agreed
aimmune
alkermes
allergy
amgen
antipsychotic
approves
arguments
awarded
benefits
big
billion
bio
brexanalone
brings
Language
unset
Current search:
drug
×
biotech
×
" life sciences "
×
" national top stories "
×
fda
×
" boston blog main "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines